Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
oral contraceptive
|
| gptkbp:activeDuring |
gptkb:ethinyl_estradiol
norethindrone |
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:associatedWith |
heart attack
stroke thromboembolism |
| gptkbp:availableIn |
tablet
various strengths |
| gptkbp:brand |
gptkb:Loestrin_Fe
Loestrin 1/20 Loestrin 24 Fe |
| gptkbp:clinicalTrials |
Phase IV
|
| gptkbp:commonName |
1 tablet daily
|
| gptkbp:contains |
gptkb:ethinyl_estradiol
norethindrone acetate |
| gptkbp:contraindication |
certain cancers
history of blood clots smoking over age 35 |
| gptkbp:dosageForm |
combination pill
|
| gptkbp:drugInterdiction |
true
hormonal contraceptive |
| gptkbp:endOfLife |
24 hours
|
| gptkbp:hasNearbyAttractions |
take as soon as remembered
|
| gptkbp:healthcare |
important for effectiveness
discuss risks with healthcare provider |
| https://www.w3.org/2000/01/rdf-schema#label |
Loestrin
|
| gptkbp:interactsWith |
gptkb:St._John's_Wort
antibiotics anticonvulsants |
| gptkbp:isRecognizedFor |
pregnant women
women with liver disease women with diabetes with vascular complications women with uncontrolled hypertension |
| gptkbp:lastProduced |
1993
|
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:United_Kingdom gptkb:United_States |
| gptkbp:nutritionalValue |
liver
|
| gptkbp:packaging |
blister pack
|
| gptkbp:producedBy |
AbbVie
|
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
headache
nausea breast tenderness mood changes |
| gptkbp:storage |
store at room temperature
|
| gptkbp:type |
norethindrone and ethinyl estradiol
|
| gptkbp:usedFor |
acne
endometriosis birth control premenstrual dysphoric disorder heavy menstrual bleeding regulating menstrual cycles |
| gptkbp:waterManagement |
urine
|